Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.52 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.51 |
| ▸ | GHSR | Q92847 | 11/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MLNR | O43193 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | NPY2R | P49146 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5649232 | 0.75 | PFKFB3 (0.56) | PFKFB3GHSRNPC1RAB9AALDH1A1 | |
| SCHEMBL7799532 | 0.73 | PFKFB3 (0.70) | PFKFB3GHSRNPC1RAB9AMLNR | |
| SCHEMBL14014137 | 0.72 | PFKFB3 (0.62) | PFKFB3GHSRNPC1RAB9AMLNR | |
| SCHEMBL15480562 | 0.72 | PFKFB3 (0.65) | PFKFB3GHSRNPC1RAB9AMLNR | |
| SCHEMBL6073809 | 0.69 | ADRB3 (0.46) | GHSR | |
| SCHEMBL12335544 | 0.68 | RXFP1 (0.59) | PFKFB3GHSRMLNRCYP2D6CYP2C9 | |
| SCHEMBL5653009 | 0.68 | NPC1 (0.58) | NPC1RAB9ACYP2C9ALDH1A1NPY2R | |
| SCHEMBL788488 | 0.68 | PFKFB3 (1.00) | PFKFB3GHSRMLNRCYP2D6CYP2C9 | |
| SCHEMBL6880743 | 0.68 | NPC1 (0.88) | NPC1RAB9AALDH1A1NPY2R | |
| SCHEMBL12334571 | 0.67 | RXFP1 (0.57) | MMP13PFKFB3GHSRMLNRCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458374-A2 | COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-09-22 | — | — | EP | claimed |
| US-20030166644-A1 | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK A/S (DK) | 2003-09-04 | — | — | US | claimed |
| WO-2003051841-A2 | COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2003-06-26 | — | — | WO | claimed |
| US-7279470-B2 | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK A/S (DK) | 2007-10-09 | — | — | US | disclosed |
| US-7067517-B2 | Use of compounds for decreasing activity of hormone-sensitive lipase | NERO NORDISK A/S (DK) | 2006-06-27 | — | — | US | disclosed |
| EP-1458374-A2 | COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-09-22 | — | — | EP | disclosed |
| EP-1458375-A2 | COMPOSITIONS FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-09-22 | — | — | EP | disclosed |
| US-20030166644-A1 | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK A/S (DK) | 2003-09-04 | — | — | US | disclosed |
| US-20030166690-A1 | Use of compounds for decreasing activity of hormone-sensitive | NOVO NORDISK A/S (DK) | 2003-09-04 | — | — | US | disclosed |
| WO-2003051841-A2 | COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051842-A2 | COMPOSITIONS DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166644-A1 | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | LIPE, PNLIP, LPL | MMP13 403/4885PFKFB3 1835/4885GHSR 55/4885 |
| US-20030166690-A1 | Use of compounds for decreasing activity of hormone-sensitive | LIPE, PNLIP, LPL | MMP13 405/4885PFKFB3 2037/4885GHSR 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.